Why Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Shaky Earnings Are Just The Beginning Of Its Problems

The market wasn't impressed with the soft earnings from Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TWSE:1762) recently. We did some analysis, and found that there are some reasons to be cautious about the headline numbers.

See our latest analysis for Chunghwa Chemical Synthesis & Biotech

How Do Unusual Items Influence Profit?

To properly understand Chunghwa Chemical Synthesis & Biotech's profit results, we need to consider the NT$11m gain attributed to unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. If Chunghwa Chemical Synthesis & Biotech doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Chunghwa Chemical Synthesis & Biotech.

Our Take On Chunghwa Chemical Synthesis & Biotech's Profit Performance

We'd posit that Chunghwa Chemical Synthesis & Biotech's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Chunghwa Chemical Synthesis & Biotech's statutory profits are better than its underlying earnings power. In further bad news, its earnings per share decreased in the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So while earnings quality is important, it's equally important to consider the risks facing Chunghwa Chemical Synthesis & Biotech at this point in time. For example, Chunghwa Chemical Synthesis & Biotech has 4 warning signs (and 1 which can't be ignored) we think you should know about.

Today we've zoomed in on a single data point to better understand the nature of Chunghwa Chemical Synthesis & Biotech's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.